1
|
Marin A, Turk KW, Schiloski K, Vives-Rodriguez A, Suh C, Uppal P, Dwyer B, Palumbo R, Budson AE. The Use of Event Related Potentials to Predict Amyloid PET Status Among Patients from a Memory Disorders Clinic. J Alzheimers Dis 2024; 100:1195-1208. [PMID: 38995774 DOI: 10.3233/jad-231038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/14/2024]
Abstract
Background Amyloid positron emission tomography (PET) scans provide in vivo evidence of Alzheimer's disease (AD); however, their high cost limits their use in standard clinical care. Event related potentials (ERPs) may represent an inexpensive and non-invasive additional method for detecting AD pathology. Objective We investigated whether ERPs, along with neuropsychological data, serve as predictors of amyloid PET status in patients with memory complaints. Methods Veterans aged 50-100 were recruited from a memory disorders clinic. Participants underwent a neuropsychological battery and an ERP auditory oddball protocol. Twenty-eight patients had a positive amyloid PET scan, and thirty-nine patients had a negative scan. Results ERP-P200 target amplitude and P200 standard latency were predictors of amyloid PET status. When submitting to ROC analysis, P200 standard latency exhibited the highest specificity and sensitivity in predicting amyloid PET positivity, correctly classifying the amyloid PET status for 86% of patients. Conclusions ERP-P200 measures are strong indicators of amyloid-β presence in patients from a memory disorder clinic. Increased P200 amplitude and decreased P200 latency in patients with a positive amyloid PET scan may be attributed to hyperactivation of perceptual bottom-up processes compensating for AD-related synaptic loss in the fronto-parietal networks.
Collapse
Affiliation(s)
- Anna Marin
- Center for Translational Cognitive Neuroscience, VA Boston Healthcare System, Boston, MA, USA
- Department of Behavioral Neuroscience, Boston University Aram V. Chobanian & Edward Avedisian School of Medicine, Boston, MA, USA
| | - Katherine W Turk
- Center for Translational Cognitive Neuroscience, VA Boston Healthcare System, Boston, MA, USA
- Alzheimer's Disease Research Center, Boston University, Boston, MA, USA
| | - Kylie Schiloski
- Center for Translational Cognitive Neuroscience, VA Boston Healthcare System, Boston, MA, USA
| | - Ana Vives-Rodriguez
- Center for Translational Cognitive Neuroscience, VA Boston Healthcare System, Boston, MA, USA
| | - Cheongmin Suh
- Center for Translational Cognitive Neuroscience, VA Boston Healthcare System, Boston, MA, USA
| | - Prayerna Uppal
- Center for Translational Cognitive Neuroscience, VA Boston Healthcare System, Boston, MA, USA
| | - Brigid Dwyer
- Center for Translational Cognitive Neuroscience, VA Boston Healthcare System, Boston, MA, USA
- Alzheimer's Disease Research Center, Boston University, Boston, MA, USA
| | - Rocco Palumbo
- Center for Translational Cognitive Neuroscience, VA Boston Healthcare System, Boston, MA, USA
| | - Andrew E Budson
- Center for Translational Cognitive Neuroscience, VA Boston Healthcare System, Boston, MA, USA
- Alzheimer's Disease Research Center, Boston University, Boston, MA, USA
| |
Collapse
|
2
|
Plaza-Rosales I, Brunetti E, Montefusco-Siegmund R, Madariaga S, Hafelin R, Ponce DP, Behrens MI, Maldonado PE, Paula-Lima A. Visual-spatial processing impairment in the occipital-frontal connectivity network at early stages of Alzheimer's disease. Front Aging Neurosci 2023; 15:1097577. [PMID: 36845655 PMCID: PMC9947357 DOI: 10.3389/fnagi.2023.1097577] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Accepted: 01/20/2023] [Indexed: 02/11/2023] Open
Abstract
Introduction Alzheimer's disease (AD) is the leading cause of dementia worldwide, but its pathophysiological phenomena are not fully elucidated. Many neurophysiological markers have been suggested to identify early cognitive impairments of AD. However, the diagnosis of this disease remains a challenge for specialists. In the present cross-sectional study, our objective was to evaluate the manifestations and mechanisms underlying visual-spatial deficits at the early stages of AD. Methods We combined behavioral, electroencephalography (EEG), and eye movement recordings during the performance of a spatial navigation task (a virtual version of the Morris Water Maze adapted to humans). Participants (69-88 years old) with amnesic mild cognitive impairment-Clinical Dementia Rating scale (aMCI-CDR 0.5) were selected as probable early AD (eAD) by a neurologist specialized in dementia. All patients included in this study were evaluated at the CDR 0.5 stage but progressed to probable AD during clinical follow-up. An equal number of matching healthy controls (HCs) were evaluated while performing the navigation task. Data were collected at the Department of Neurology of the Clinical Hospital of the Universidad de Chile and the Department of Neuroscience of the Faculty of Universidad de Chile. Results Participants with aMCI preceding AD (eAD) showed impaired spatial learning and their visual exploration differed from the control group. eAD group did not clearly prefer regions of interest that could guide solving the task, while controls did. The eAD group showed decreased visual occipital evoked potentials associated with eye fixations, recorded at occipital electrodes. They also showed an alteration of the spatial spread of activity to parietal and frontal regions at the end of the task. The control group presented marked occipital activity in the beta band (15-20 Hz) at early visual processing time. The eAD group showed a reduction in beta band functional connectivity in the prefrontal cortices reflecting poor planning of navigation strategies. Discussion We found that EEG signals combined with visual-spatial navigation analysis, yielded early and specific features that may underlie the basis for understanding the loss of functional connectivity in AD. Still, our results are clinically promising for early diagnosis required to improve quality of life and decrease healthcare costs.
Collapse
Affiliation(s)
- Iván Plaza-Rosales
- Department of Medical Technology, Faculty of Medicine, Universidad de Chile, Santiago, Chile,Biomedical Neuroscience Institute, Faculty of Medicine, Universidad de Chile, Santiago, Chile
| | - Enzo Brunetti
- Biomedical Neuroscience Institute, Faculty of Medicine, Universidad de Chile, Santiago, Chile,Institute of Neurosurgery and Brain Research Dr. Alfonso Asenjo, Santiago, Chile,Department of Neuroscience, Faculty of Medicine, Universidad de Chile, Santiago, Chile
| | - Rodrigo Montefusco-Siegmund
- Faculty of Medicine, Institute of Locomotor System and Rehabilitation, Universidad Austral de Chile, Valdivia, Chile
| | - Samuel Madariaga
- Biomedical Neuroscience Institute, Faculty of Medicine, Universidad de Chile, Santiago, Chile
| | - Rodrigo Hafelin
- Biomedical Neuroscience Institute, Faculty of Medicine, Universidad de Chile, Santiago, Chile
| | - Daniela P. Ponce
- Department of Neurology and Neurosurgery, Hospital Clínico Universidad de Chile, Santiago, Chile,Faculty of Medicine, Center for Advanced Clinical Research, Universidad de Chile, Santiago, Chile
| | - María Isabel Behrens
- Department of Neuroscience, Faculty of Medicine, Universidad de Chile, Santiago, Chile,Department of Neurology and Neurosurgery, Hospital Clínico Universidad de Chile, Santiago, Chile,Faculty of Medicine, Center for Advanced Clinical Research, Universidad de Chile, Santiago, Chile,Department of Neurology and Psychiatry, Clínica Alemana-Universidad del Desarrollo, Santiago, Chile
| | - Pedro E. Maldonado
- Biomedical Neuroscience Institute, Faculty of Medicine, Universidad de Chile, Santiago, Chile,Department of Neuroscience, Faculty of Medicine, Universidad de Chile, Santiago, Chile,Pedro E. Maldonado,
| | - Andrea Paula-Lima
- Biomedical Neuroscience Institute, Faculty of Medicine, Universidad de Chile, Santiago, Chile,Department of Neuroscience, Faculty of Medicine, Universidad de Chile, Santiago, Chile,Institute for Research in Dental Sciences, Faculty of Dentistry, Universidad de Chile, Santiago, Chile,*Correspondence: Andrea Paula-Lima,
| |
Collapse
|
3
|
Choi J, Ku B, Doan DNT, Park J, Cha W, Kim JU, Lee KH. Prefrontal EEG slowing, synchronization, and ERP peak latency in association with predementia stages of Alzheimer's disease. Front Aging Neurosci 2023; 15:1131857. [PMID: 37032818 PMCID: PMC10076640 DOI: 10.3389/fnagi.2023.1131857] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2022] [Accepted: 03/06/2023] [Indexed: 04/11/2023] Open
Abstract
Background Early screening of elderly individuals who are at risk of dementia allows timely medical interventions to prevent disease progression. The portable and low-cost electroencephalography (EEG) technique has the potential to serve it. Objective We examined prefrontal EEG and event-related potential (ERP) variables in association with the predementia stages of Alzheimer's disease (AD). Methods One hundred elderly individuals were recruited from the GARD cohort. The participants were classified into four groups according to their amyloid beta deposition (A+ or A-) and neurodegeneration status (N+ or N-): cognitively normal (CN; A-N-, n = 27), asymptomatic AD (aAD; A + N-, n = 15), mild cognitive impairment (MCI) with AD pathology (pAD; A+N+, n = 16), and MCI with non-AD pathology (MCI(-); A-N+, n = 42). Prefrontal resting-state eyes-closed EEG measurements were recorded for five minutes and auditory ERP measurements were recorded for 8 min. Three variables of median frequency (MDF), spectrum triangular index (STI), and positive-peak latency (PPL) were employed to reflect EEG slowing, temporal synchrony, and ERP latency, respectively. Results Decreasing prefrontal MDF and increasing PPL were observed in the MCI with AD pathology. Interestingly, after controlling for age, sex, and education, we found a significant negative association between MDF and the aAD and pAD stages with an odds ratio (OR) of 0.58. Similarly, PPL exhibited a significant positive association with these AD stages with an OR of 2.36. Additionally, compared with the MCI(-) group, significant negative associations were demonstrated by the aAD group with STI and those in the pAD group with MDF with ORs of 0.30 and 0.42, respectively. Conclusion Slow intrinsic EEG oscillation is associated with MCI due to AD, and a delayed ERP peak latency is likely associated with general cognitive impairment. MCI individuals without AD pathology exhibited better cortical temporal synchronization and faster EEG oscillations than those with aAD or pAD. Significance The EEG/ERP variables obtained from prefrontal EEG techniques are associated with early cognitive impairment due to AD and non-AD pathology. This result suggests that prefrontal EEG/ERP metrics may serve as useful indicators to screen elderly individuals' early stages on the AD continuum as well as overall cognitive impairment.
Collapse
Affiliation(s)
- Jungmi Choi
- Human Anti-Aging Standards Research Institute, Uiryeong-gun, Republic of Korea
| | - Boncho Ku
- Digital Health Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea
| | - Dieu Ni Thi Doan
- Digital Health Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea
- School of Korean Convergence Medical Science, University of Science and Technology, Daejeon, Republic of Korea
| | - Junwoo Park
- Gwangju Alzheimer’s Disease and Related Dementias Cohort Research Center, Chosun University, Gwangju, Republic of Korea
| | - Wonseok Cha
- Human Anti-Aging Standards Research Institute, Uiryeong-gun, Republic of Korea
| | - Jaeuk U. Kim
- Digital Health Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea
- School of Korean Convergence Medical Science, University of Science and Technology, Daejeon, Republic of Korea
- *Correspondence: Jaeuk U. Kim,
| | - Kun Ho Lee
- Gwangju Alzheimer’s Disease and Related Dementias Cohort Research Center, Chosun University, Gwangju, Republic of Korea
- Department of Biomedical Science, Chosun University, Gwangju, Republic of Korea
- Dementia Research Group, Korea Brain Research Institute, Daegu, Republic of Korea
- Kun Ho Lee,
| |
Collapse
|
4
|
Treatment effects on event-related EEG potentials and oscillations in Alzheimer's disease. Int J Psychophysiol 2022; 177:179-201. [PMID: 35588964 DOI: 10.1016/j.ijpsycho.2022.05.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Revised: 05/11/2022] [Accepted: 05/12/2022] [Indexed: 11/23/2022]
Abstract
Alzheimer's disease dementia (ADD) is the most diffuse neurodegenerative disorder belonging to mild cognitive impairment (MCI) and dementia in old persons. This disease is provoked by an abnormal accumulation of amyloid-beta and tauopathy proteins in the brain. Very recently, the first disease-modifying drug has been licensed with reserve (i.e., Aducanumab). Therefore, there is a need to identify and use biomarkers probing the neurophysiological underpinnings of human cognitive functions to test the clinical efficacy of that drug. In this regard, event-related electroencephalographic potentials (ERPs) and oscillations (EROs) are promising candidates. Here, an Expert Panel from the Electrophysiology Professional Interest Area of the Alzheimer's Association and Global Brain Consortium reviewed the field literature on the effects of the most used symptomatic drug against ADD (i.e., Acetylcholinesterase inhibitors) on ERPs and EROs in ADD patients with MCI and dementia at the group level. The most convincing results were found in ADD patients. In those patients, Acetylcholinesterase inhibitors partially normalized ERP P300 peak latency and amplitude in oddball paradigms using visual stimuli. In these same paradigms, those drugs partially normalize ERO phase-locking at the theta band (4-7 Hz) and spectral coherence between electrode pairs at the gamma (around 40 Hz) band. These results are of great interest and may motivate multicentric, double-blind, randomized, and placebo-controlled clinical trials in MCI and ADD patients for final cross-validation.
Collapse
|
5
|
Güntekin B, Aktürk T, Arakaki X, Bonanni L, Del Percio C, Edelmayer R, Farina F, Ferri R, Hanoğlu L, Kumar S, Lizio R, Lopez S, Murphy B, Noce G, Randall F, Sack AT, Stocchi F, Yener G, Yıldırım E, Babiloni C. Are there consistent abnormalities in event-related EEG oscillations in patients with Alzheimer's disease compared to other diseases belonging to dementia? Psychophysiology 2022; 59:e13934. [PMID: 34460957 DOI: 10.1111/psyp.13934] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2021] [Revised: 07/31/2021] [Accepted: 08/09/2021] [Indexed: 01/30/2023]
Abstract
Cerebrospinal and structural-molecular neuroimaging in-vivo biomarkers are recommended for diagnostic purposes in Alzheimer's disease (AD) and other dementias; however, they do not explain the effects of AD neuropathology on neurophysiological mechanisms underpinning cognitive processes. Here, an Expert Panel from the Electrophysiology Professional Interest Area of the Alzheimer's Association reviewed the field literature and reached consensus on the event-related electroencephalographic oscillations (EROs) that show consistent abnormalities in patients with significant cognitive deficits due to Alzheimer's, Parkinson's (PD), Lewy body (LBD), and cerebrovascular diseases. Converging evidence from oddball paradigms showed that, as compared to cognitively unimpaired (CU) older adults, AD patients had lower amplitude in widespread delta (>4 Hz) and theta (4-7 Hz) phase-locked EROs as a function of disease severity. Similar effects were also observed in PD, LBD, and/or cerebrovascular cognitive impairment patients. Non-phase-locked alpha (8-12 Hz) and beta (13-30 Hz) oscillations were abnormally reduced (event-related desynchronization, ERD) in AD patients relative to CU. However, studies on patients with other dementias remain lacking. Delta and theta phase-locked EROs during oddball tasks may be useful neurophysiological biomarkers of cognitive systems at work in heuristic and intervention clinical trials performed in AD patients, but more research is needed regarding their potential role for other dementias.
Collapse
Affiliation(s)
- Bahar Güntekin
- Research Institute for Health Sciences and Technologies (SABITA), Regenerative and Restorative Medicine Research Center (REMER), Clinical Electrophysiology, Neuroimaging and Neuromodulation Lab, Istanbul Medipol University, Istanbul, Turkey
- Department of Biophysics, School of Medicine, Istanbul Medipol University, Istanbul, Turkey
| | - Tuba Aktürk
- Research Institute for Health Sciences and Technologies (SABITA), Regenerative and Restorative Medicine Research Center (REMER), Clinical Electrophysiology, Neuroimaging and Neuromodulation Lab, Istanbul Medipol University, Istanbul, Turkey
- Vocational School, Program of Electroneurophysiology, Istanbul Medipol University, Istanbul, Turkey
- Department of Cognitive Neuroscience, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, Netherlands
| | | | - Laura Bonanni
- Department of Neuroscience Imaging and Clinical Sciences and CESI, University G d'Annunzio of Chieti-Pescara, Chieti, Italy
| | - Claudio Del Percio
- Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Rome, Italy
| | | | - Francesca Farina
- School of Psychology, Trinity College Dublin, Dublin, Ireland
- Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
| | | | - Lütfü Hanoğlu
- Department of Neurology, School of Medicine, Istanbul Medipol University, Istanbul, Turkey
| | - Sanjeev Kumar
- Adult Neurodevelopmental and Geriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
- Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
| | | | - Susanna Lopez
- Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Rome, Italy
| | | | | | - Fiona Randall
- Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA
| | - Alexander T Sack
- Department of Cognitive Neuroscience, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, Netherlands
| | - Fabrizio Stocchi
- Institute for Research and Medical Care, IRCCS San Raffaele Pisana, Rome, Italy
| | - Görsev Yener
- Izmir Biomedicine and Genome Center, Dokuz Eylul University Health Campus, Izmir, Turkey
| | - Ebru Yıldırım
- Research Institute for Health Sciences and Technologies (SABITA), Regenerative and Restorative Medicine Research Center (REMER), Clinical Electrophysiology, Neuroimaging and Neuromodulation Lab, Istanbul Medipol University, Istanbul, Turkey
- Vocational School, Program of Electroneurophysiology, Istanbul Medipol University, Istanbul, Turkey
| | - Claudio Babiloni
- Alzheimer's Association, Chicago, Illinois, USA
- Institute for Research and Medical Care, Hospital San Raffaele of Cassino, Cassino, Italy
| |
Collapse
|
6
|
García Pretelt FJ, Suárez Relevo JX, Aguillón D, Lopera F, Ochoa JF, Tobón Quintero CA. Automatic Classification of Subjects of the PSEN1-E280A Family at Risk of Developing Alzheimer’s Disease Using Machine Learning and Resting State Electroencephalography. J Alzheimers Dis 2022; 87:817-832. [DOI: 10.3233/jad-210148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Background: The study of genetic variant carriers provides an opportunity to identify neurophysiological changes in preclinical stages. Electroencephalography (EEG) is a low-cost and minimally invasive technique which, together with machine learning, provide the possibility to construct systems that classify subjects that might develop Alzheimer’s disease (AD). Objective: The aim of this paper is to evaluate the capacity of the machine learning techniques to classify healthy Non-Carriers (NonCr) from Asymptomatic Carriers (ACr) of PSEN1-E280A variant for autosomal dominant Alzheimer’s disease (ADAD), using spectral features from EEG channels and brain-related independent components (ICs) obtained using independent component analysis (ICA). Methods: EEG was recorded in 27 ACr and 33 NonCr. Statistical significance analysis was applied to spectral information from channels and group ICA (gICA), standardized low-resolution tomography (sLORETA) analysis was applied over the IC as well. Strategies for feature selection and classification like Chi-square, mutual informationm and support vector machines (SVM) were evaluated over the dataset. Results: A test accuracy up to 83% was obtained by implementing a SVM with spectral features derived from gICA. The main findings are related to theta and beta rhythms, generated in the parietal and occipital regions, like the precuneus and superior parietal lobule. Conclusion: Promising models for classification of preclinical AD due to PSEN-1-E280A variant can be trained using spectral features, and the importance of the beta band and precuneus region is highlighted in asymptomatic stages, opening up the possibility of its use as a screening methodology.
Collapse
Affiliation(s)
- Francisco J. García Pretelt
- Bioinstrumentation and Clinical Engineering Research Group (GIBIC), Bioengineering Program, Universidad de Antioquia, Medellín, Colombia
- Neuropsychology and Behavior Group (GRUNECO), Medical School, Universidad de Antioquia, Medellín, Colombia
| | - Jazmín X. Suárez Relevo
- Bioinstrumentation and Clinical Engineering Research Group (GIBIC), Bioengineering Program, Universidad de Antioquia, Medellín, Colombia
- Neuropsychology and Behavior Group (GRUNECO), Medical School, Universidad de Antioquia, Medellín, Colombia
| | - David Aguillón
- Neuroscience Group of Antioquia (GNA), Medical School, Universidad de Antioquia, Medellín, Colombia
- Neuropsychology and Behavior Group (GRUNECO), Medical School, Universidad de Antioquia, Medellín, Colombia
| | - Francisco Lopera
- Neuroscience Group of Antioquia (GNA), Medical School, Universidad de Antioquia, Medellín, Colombia
| | - John Fredy Ochoa
- Bioinstrumentation and Clinical Engineering Research Group (GIBIC), Bioengineering Program, Universidad de Antioquia, Medellín, Colombia
- Neuropsychology and Behavior Group (GRUNECO), Medical School, Universidad de Antioquia, Medellín, Colombia
| | - Carlos A. Tobón Quintero
- Neuroscience Group of Antioquia (GNA), Medical School, Universidad de Antioquia, Medellín, Colombia
- Neuropsychology and Behavior Group (GRUNECO), Medical School, Universidad de Antioquia, Medellín, Colombia
| |
Collapse
|
7
|
Ibanez A, Yokoyama JS, Possin KL, Matallana D, Lopera F, Nitrini R, Takada LT, Custodio N, Sosa Ortiz AL, Avila-Funes JA, Behrens MI, Slachevsky A, Myers RM, Cochran JN, Brusco LI, Bruno MA, Brucki SMD, Pina-Escudero SD, Okada de Oliveira M, Donnelly Kehoe P, Garcia AM, Cardona JF, Santamaria-Garcia H, Moguilner S, Duran-Aniotz C, Tagliazucchi E, Maito M, Longoria Ibarrola EM, Pintado-Caipa M, Godoy ME, Bakman V, Javandel S, Kosik KS, Valcour V, Miller BL. The Multi-Partner Consortium to Expand Dementia Research in Latin America (ReDLat): Driving Multicentric Research and Implementation Science. Front Neurol 2021; 12:631722. [PMID: 33776890 PMCID: PMC7992978 DOI: 10.3389/fneur.2021.631722] [Citation(s) in RCA: 47] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2020] [Accepted: 02/15/2021] [Indexed: 12/17/2022] Open
Abstract
Dementia is becoming increasingly prevalent in Latin America, contrasting with stable or declining rates in North America and Europe. This scenario places unprecedented clinical, social, and economic burden upon patients, families, and health systems. The challenges prove particularly pressing for conditions with highly specific diagnostic and management demands, such as frontotemporal dementia. Here we introduce a research and networking initiative designed to tackle these ensuing hurdles, the Multi-partner consortium to expand dementia research in Latin America (ReDLat). First, we present ReDLat's regional research framework, aimed at identifying the unique genetic, social, and economic factors driving the presentation of frontotemporal dementia and Alzheimer's disease in Latin America relative to the US. We describe ongoing ReDLat studies in various fields and ongoing research extensions. Then, we introduce actions coordinated by ReDLat and the Latin America and Caribbean Consortium on Dementia (LAC-CD) to develop culturally appropriate diagnostic tools, regional visibility and capacity building, diplomatic coordination in local priority areas, and a knowledge-to-action framework toward a regional action plan. Together, these research and networking initiatives will help to establish strong cross-national bonds, support the implementation of regional dementia plans, enhance health systems' infrastructure, and increase translational research collaborations across the continent.
Collapse
Affiliation(s)
- Agustin Ibanez
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
- Cognitive Neuroscience Center, Universidad de San Andrés, Buenos Aires, Argentina
- National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina
- School of Psychology, Center for Social and Cognitive Neuroscience, Latin American Institute for Brain Health (BrainLat), Universidad Adolfo Ibanez, Adolfo Ibanez University, Santiago, Chile
| | - Jennifer S. Yokoyama
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
- Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, United States
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States
| | - Katherine L. Possin
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
- Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, United States
| | - Diana Matallana
- Psychiatry Department, School of Medicine, Aging Institute, Pontificia Universidad Javeriana, Bogotá, Colombia
- Memory and Cognition Clinic, Intellectus, Hospital Universitario San Ignacio, Bogotá, Colombia
- Mental Health Unit, Hospital Universitario Santa Fe de Bogotá, Bogotá, Colombia
| | - Francisco Lopera
- Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellín, Colombia
| | - Ricardo Nitrini
- Cognitive and Behavioral Neurology Unit, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, Brazil
| | - Leonel T. Takada
- Cognitive and Behavioral Neurology Unit, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, Brazil
| | - Nilton Custodio
- Unit Cognitive Impairment and Dementia Prevention, Cognitive Neurology Center, Peruvian Institute of Neurosciences, Lima, Perú
| | - Ana Luisa Sosa Ortiz
- Instituto Nacional de Neurologia y Neurocirugia MVS, Universidad Nacional Autonoma de Mexico, Mexico, Mexico
| | - José Alberto Avila-Funes
- Department of Geriatrics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico
- Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Bordeaux, France
| | - Maria Isabel Behrens
- Centro de Investigación Clínica Avanzada, Hospital Clínico, Facultad de Medicina Universidad de Chile, Santiago, Chile
- Departamento de Neurología y Neurocirugía, Hospital Clínico Universidad de Chile, Santiago, Chile
- Departamento de Neurociencia, Facultad de Medicina Universidad de Chile, Santiago, Chile
- Clínica Alemana Santiago, Universidad del Desarrollo, Santiago, Chile
| | - Andrea Slachevsky
- Clínica Alemana Santiago, Universidad del Desarrollo, Santiago, Chile
- Geroscience Center for Brain Health and Metabolism (GERO), Santiago, Chile
- Neuropsychology and Clinical Neuroscience Laboratory, Physiopathology Department, Institute of Biomedical Sciences, Neuroscience and East Neuroscience, Santiago, Chile
- Faculty of Medicine, University of Chile, Santiago, Chile
- Memory and Neuropsychiatric Clinic (CMYN) Neurology Department, Faculty of Medicine, Hospital del Salvador, University of Chile, Santiago, Chile
| | - Richard M. Myers
- Hudson Alpha Institute for Biotechnology, Huntsville, AL, United States
| | | | - Luis Ignacio Brusco
- Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
- ALZAR – Alzheimer, Buenos Aires, Argentina
| | - Martin A. Bruno
- National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina
- Facultad Ciencias Médicas, Instituto Ciencias Biomédicas, Universidad Católica de Cuyo, San Juan, Argentina
| | - Sonia M. D. Brucki
- Cognitive and Behavioral Neurology Unit, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, Brazil
- Hospital Santa Marcelina, São Paulo, São Paulo, Brazil
| | - Stefanie Danielle Pina-Escudero
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
- Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, United States
| | - Maira Okada de Oliveira
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
- Cognitive and Behavioral Neurology Unit, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, Brazil
- Hospital Santa Marcelina, São Paulo, São Paulo, Brazil
| | - Patricio Donnelly Kehoe
- National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina
- Multimedia Signal Processing Group - Neuroimage Division, French-Argentine International Center for Information and Systems Sciences, Rosario, Argentina
| | - Adolfo M. Garcia
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
- Cognitive Neuroscience Center, Universidad de San Andrés, Buenos Aires, Argentina
- National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina
- Faculty of Education, National University of Cuyo, Mendoza, Argentina
| | | | - Hernando Santamaria-Garcia
- Memory and Cognition Clinic, Intellectus, Hospital Universitario San Ignacio, Bogotá, Colombia
- Ph.D. Program in Neuroscience, Department of Psychiatry, Physiology, Pontificia Universidad Javeriana, Bogotá, Colombia
| | - Sebastian Moguilner
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
| | - Claudia Duran-Aniotz
- School of Psychology, Center for Social and Cognitive Neuroscience, Latin American Institute for Brain Health (BrainLat), Universidad Adolfo Ibanez, Adolfo Ibanez University, Santiago, Chile
| | - Enzo Tagliazucchi
- Departamento de Física, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Marcelo Maito
- Cognitive Neuroscience Center, Universidad de San Andrés, Buenos Aires, Argentina
| | | | - Maritza Pintado-Caipa
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
- Unit Cognitive Impairment and Dementia Prevention, Cognitive Neurology Center, Peruvian Institute of Neurosciences, Lima, Perú
| | - Maria Eugenia Godoy
- Cognitive Neuroscience Center, Universidad de San Andrés, Buenos Aires, Argentina
| | - Vera Bakman
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
| | - Shireen Javandel
- Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, United States
| | - Kenneth S. Kosik
- Department of Molecular, Cellular, and Developmental Biology, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA, United States
| | - Victor Valcour
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
- Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, United States
| | - Bruce L. Miller
- The Global Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, CA, United States
- The Global Brain Health Institute (GBHI), Trinity College Dublin, Dublin, Ireland
- Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, United States
| |
Collapse
|
8
|
Fuller JT, Cronin-Golomb A, Gatchel JR, Norton DJ, Guzmán-Vélez E, Jacobs HIL, Hanseeuw B, Pardilla-Delgado E, Artola A, Baena A, Bocanegra Y, Kosik KS, Chen K, Tariot PN, Johnson K, Sperling RA, Reiman EM, Lopera F, Quiroz YT. Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer's Disease: A Comprehensive Review of the Colombian Kindred. JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE 2020; 6:112-120. [PMID: 30756118 DOI: 10.14283/jpad.2019.6] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The study of individuals with autosomal dominant Alzheimer's disease affords one of the best opportunities to characterize the biological and cognitive changes of Alzheimer's disease that occur over the course of the preclinical and symptomatic stages. Unifying the knowledge gained from the past three decades of research in the world's largest single-mutation autosomal dominant Alzheimer's disease kindred - a family in Antioquia, Colombia with the E280A mutation in the Presenilin1 gene - will provide new directions for Alzheimer's research and a framework for generalizing the findings from this cohort to the more common sporadic form of Alzheimer's disease. As this specific mutation is virtually 100% penetrant for the development of the disease by midlife, we use a previously defined median age of onset for mild cognitive impairment for this cohort to examine the trajectory of the biological and cognitive markers of the disease as a function of the carriers' estimated years to clinical onset. Studies from this cohort suggest that structural and functional brain abnormalities - such as cortical thinning and hyperactivation in memory networks - as well as differences in biofluid and in vivo measurements of Alzheimer's-related pathological proteins distinguish Presenilin1 E280A mutation carriers from non-carriers as early as childhood, or approximately three decades before the median age of onset of clinical symptoms. We conclude our review with discussion on future directions for Alzheimer's disease research, with specific emphasis on ways to design studies that compare the generalizability of research in autosomal dominant Alzheimer's disease to the larger sporadic Alzheimer's disease population.
Collapse
Affiliation(s)
- J T Fuller
- Yakeel T. Quiroz, PhD Assistant Professor, Harvard Medical School, Departments of Psychiatry and Neurology, Massachusetts General Hospital, 100 1st Avenue, Building 39, Suite 101, Charlestown, MA 02129, Phone (617) 643-5944; Fax: (617) 726-5760, E-mail:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Kim B, Shin J, Kim Y, Choi JH. Destruction of ERP responses to deviance in an auditory oddball paradigm in amyloid infusion mice with memory deficits. PLoS One 2020; 15:e0230277. [PMID: 32160242 PMCID: PMC7065782 DOI: 10.1371/journal.pone.0230277] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2019] [Accepted: 02/25/2020] [Indexed: 11/24/2022] Open
Abstract
The amyloid-β (Aβ) oligomer is considered one of the major pathogens responsible for neuronal and synaptic loss in Alzheimer’s disease (AD) brains. Although the neurotoxic mechanisms of Aβ have been widely investigated, experimental evidence for the direct linkage between neural signaling and cognitive impairments in association with peptide oligomers is lacking. Here, we conducted an auditory oddball paradigm utilizing an Aβ-infused Alzheimer’s disease mouse model and interpreted the results based on Y-maze behavioral tests. We acutely injected Aβ oligomers into the intracerebroventricular brain region of normal mice to induce Aβ-associated cognitive impairments. During the auditory oddball paradigm, electroencephalograms (EEG) were recorded from frontal and parietal cortex of Aβ-infused and control mice. The event-related potentials (ERPs) elicited by auditory stimuli showed no significant difference in Aβ-infused mice compared to control mice. On the other hand, the differential ERP signature elicited by oddball sound stimuli was destructed in the Aβ-infused mice group. We noticed that ERP traces to standard and deviant tones were not significantly different in the Aβ group, while the control group showed differences in the amplitude of ERP components. In particular, the difference in the first negative component (N1) between standard and deviant tone, which indexes the sensory memory system, was significantly reduced in the parietal cortex of Aβ-infused mice. These findings demonstrate the direct influence of Aβ oligomers on the functional integrity of cortical areas in vivo. Furthermore, the N1 amplitude difference may provide a potential marker of sensory memory deficits in a mouse model of AD and yield additional targets for drug assessment in AD.
Collapse
Affiliation(s)
- Bowon Kim
- Center for Neuroscience, Korea Institute of Science and Technology, Seoul, Republic of Korea
- Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology, Seoul, Republic of Korea
| | - Jisu Shin
- Department of Pharmacy, Yonsei University, Incheon, Republic of Korea
- Yonsei Institute of Pharmaceutical Science, Yonsei University, Incheon, Republic of Korea
| | - YoungSoo Kim
- Department of Pharmacy, Yonsei University, Incheon, Republic of Korea
- Yonsei Institute of Pharmaceutical Science, Yonsei University, Incheon, Republic of Korea
- Integrated Science and Engineering Division, Yonsei University, Incheon, Republic of Korea
- * E-mail: (YK); (JHC)
| | - Jee Hyun Choi
- Center for Neuroscience, Korea Institute of Science and Technology, Seoul, Republic of Korea
- Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology, Seoul, Republic of Korea
- * E-mail: (YK); (JHC)
| |
Collapse
|
10
|
What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. Neurobiol Aging 2020; 85:58-73. [DOI: 10.1016/j.neurobiolaging.2019.09.008] [Citation(s) in RCA: 77] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2019] [Revised: 08/27/2019] [Accepted: 09/14/2019] [Indexed: 01/14/2023]
|
11
|
Guzmán-Vélez E, Jaimes S, Aguirre-Acevedo DC, Norton DJ, Papp KV, Amariglio R, Rentz D, Baena A, Henao E, Tirado V, Muñoz C, Giraldo M, Sperling RA, Lopera F, Quiroz YT. A Three-Factor Structure of Cognitive Functioning Among Unimpaired Carriers and Non-Carriers of Autosomal-Dominant Alzheimer's Disease. J Alzheimers Dis 2019; 65:107-115. [PMID: 30040714 DOI: 10.3233/jad-180078] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
BACKGROUND There is a need to find cognitive markers that can help identify individuals at risk for Alzheimer's disease (AD), and that can be used to reliably measure cognitive decline. OBJECTIVE We tested whether a theoretically driven three-factor structure would characterize cognitive functioning in individuals who are genetically-determined to develop AD due to a mutation in Presenilin-1 (PSEN1) gene. We also examined whether these factors could distinguish cognitively unimpaired PSEN1 mutation carriers from age-matched non-carrier family members. METHODS 1,395 cognitively unimpaired members of a Colombian kindred with the PSEN1 E280A mutation were included in the study. A confirmatory factor analysis examined the fit of the three-factor model comprising episodic memory (MMSE memory recall, CERAD-COL Word list recall, and Constructional praxis recall), executive function (Phonemic fluency and WCST perseverative errors), and psychomotor processing speed (TMT-A and WAIS-III Digit Symbol). RESULTS The three-factor model provided an excellent fit for all participants (p = 0.24; RMSEA = 0.01). Further, the episodic memory (p = 0.0004, d = 0.25) and executive functioning (p = 0.001, d = 0.18) factors distinguished cognitively unimpaired carriers from non-carriers. The episodic memory factor provided the earliest indication of preclinical cognitive decline at 35 years of age, nine years before individuals' estimated age of clinical onset. CONCLUSIONS The three theoretically derived cognitive factors provide a reliable measure of cognition and may be useful for the early detection of AD, as well as for measuring disease progression. However, longitudinal studies are needed to confirm that these factors can be used to track the progression of cognitive decline in preclinical AD.
Collapse
Affiliation(s)
- Edmarie Guzmán-Vélez
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Sehily Jaimes
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Daniel C Aguirre-Acevedo
- Grupo Académico de Epidemiología Clínica, School of Medicine, University of Antioquia, Medellín, Colombia.,Grupo de Neurociencias de Antioquia, School of Medicine, University of Antioquia, Medellín, Colombia
| | - Daniel J Norton
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Kathryn V Papp
- Department of Neurology, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, MA, USA.,Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Rebecca Amariglio
- Department of Neurology, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, MA, USA.,Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Dorene Rentz
- Department of Neurology, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, MA, USA.,Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Ana Baena
- Grupo de Neurociencias de Antioquia, School of Medicine, University of Antioquia, Medellín, Colombia
| | - Eliana Henao
- Grupo de Neurociencias de Antioquia, School of Medicine, University of Antioquia, Medellín, Colombia
| | - Victoria Tirado
- Grupo de Neurociencias de Antioquia, School of Medicine, University of Antioquia, Medellín, Colombia
| | - Claudia Muñoz
- Grupo de Neurociencias de Antioquia, School of Medicine, University of Antioquia, Medellín, Colombia
| | - Margarita Giraldo
- Grupo de Neurociencias de Antioquia, School of Medicine, University of Antioquia, Medellín, Colombia
| | - Reisa A Sperling
- Department of Neurology, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, MA, USA.,Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Francisco Lopera
- Grupo de Neurociencias de Antioquia, School of Medicine, University of Antioquia, Medellín, Colombia
| | - Yakeel T Quiroz
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.,Grupo de Neurociencias de Antioquia, School of Medicine, University of Antioquia, Medellín, Colombia.,Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
12
|
Deficits of visuospatial working memory and executive function in single- versus multiple-domain amnestic mild cognitive impairment: A combined ERP and sLORETA study. Clin Neurophysiol 2019; 130:739-751. [DOI: 10.1016/j.clinph.2019.01.025] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Revised: 01/22/2019] [Accepted: 01/29/2019] [Indexed: 02/07/2023]
|
13
|
Event-related potential correlates of recognition memory in asymptomatic individuals with CADASIL. Brain Res 2018; 1707:74-78. [PMID: 30445028 DOI: 10.1016/j.brainres.2018.11.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2018] [Revised: 11/03/2018] [Accepted: 11/12/2018] [Indexed: 11/22/2022]
Abstract
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common form of hereditary stroke disorder and is caused by mutations of the NOTCH3 gene. Cognitive decline in CADASIL is characterized by early impairments of attention, memory, and executive functions. Studying asymptomatic individuals with CADASIL offers a unique genetic model to understand preclinical vascular cognitive impairment and dementia. This study aimed at examine whether early preclinical physiological changes could be observed in asymptomatic individuals with CADASIL, who will go on to develop vascular cognitive impairment and dementia later in life. Twenty-nine individuals (mean age: 54.1 years old) were included in the study; five CADASIL NOTCH3 mutation carriers and twenty-five age-matched non-carriers. Participants underwent a comprehensive clinical evaluation and neuropsychological testing. Event-related potentials (ERPs) were recorded during a picture recognition memory task. Analyses focused on the early frontal effect and parietal effect ERP components associated with familiarity and recollection memory. There were no differences between groups in behavioral performance during recognition memory discrimination or cognitive performance. Compared to non-carriers, CADASIL carriers had decreased amplitudes in both ERP components for hits and correct rejections. Among mutation carriers, lower amplitude at 500-600 ms in the left parietal region of interest for correct rejections was correlated with worse performance on measures of semantic fluency and inhibitory control. We conclude that cognitively unimpaired CADASIL carriers showed abnormalities in the neural correlates of recognition memory, years before clinical onset. Early disruptions of fronto-subcortical networks may explain preclinical changes in brain function during recognition memory. This work also demonstrates the potential usefulness of ERP brain correlates as preclinical markers of vascular dementia.
Collapse
|
14
|
Sami S, Williams N, Hughes LE, Cope TE, Rittman T, Coyle-Gilchrist ITS, Henson RN, Rowe JB. Neurophysiological signatures of Alzheimer's disease and frontotemporal lobar degeneration: pathology versus phenotype. Brain 2018; 141:2500-2510. [PMID: 30060017 PMCID: PMC6061803 DOI: 10.1093/brain/awy180] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2017] [Revised: 04/27/2018] [Accepted: 05/17/2018] [Indexed: 01/21/2023] Open
Abstract
The disruption of brain networks is characteristic of neurodegenerative dementias. However, it is controversial whether changes in connectivity reflect only the functional anatomy of disease, with selective vulnerability of brain networks, or the specific neurophysiological consequences of different neuropathologies within brain networks. We proposed that the oscillatory dynamics of cortical circuits reflect the tuning of local neural interactions, such that different pathologies are selective in their impact on the frequency spectrum of oscillations, whereas clinical syndromes reflect the anatomical distribution of pathology and physiological change. To test this hypothesis, we used magnetoencephalography from five patient groups, representing dissociated pathological subtypes and distributions across frontal, parietal and temporal lobes: amnestic Alzheimer's disease, posterior cortical atrophy, and three syndromes associated with frontotemporal lobar degeneration. We measured effective connectivity with graph theory-based measures of local efficiency, using partial directed coherence between sensors. As expected, each disease caused large-scale changes of neurophysiological brain networks, with reductions in local efficiency compared to controls. Critically however, the frequency range of altered connectivity was consistent across clinical syndromes that shared a likely underlying pathology, whilst the localization of changes differed between clinical syndromes. Multivariate pattern analysis of the frequency-specific topographies of local efficiency separated the disorders from each other and from controls (accuracy 62% to 100%, according to the groups' differences in likely pathology and clinical syndrome). The data indicate that magnetoencephalography has the potential to reveal specific changes in neurophysiology resulting from neurodegenerative disease. Our findings confirm that while clinical syndromes have characteristic anatomical patterns of abnormal connectivity that may be identified with other methods like structural brain imaging, the different mechanisms of neurodegeneration also cause characteristic spectral signatures of physiological coupling that are not accessible with structural imaging nor confounded by the neurovascular signalling of functional MRI. We suggest that these spectral characteristics of altered connectivity are the result of differential disruption of neuronal microstructure and synaptic physiology by Alzheimer's disease versus frontotemporal lobar degeneration.
Collapse
Affiliation(s)
- Saber Sami
- Department of Clinical Neurosciences, University of Cambridge, UK
| | | | - Laura E Hughes
- Department of Clinical Neurosciences, University of Cambridge, UK
- Medical Research Council Cognition and Brain Sciences Unit, Cambridge, UK
| | - Thomas E Cope
- Department of Clinical Neurosciences, University of Cambridge, UK
| | - Timothy Rittman
- Department of Clinical Neurosciences, University of Cambridge, UK
| | | | - Richard N Henson
- Medical Research Council Cognition and Brain Sciences Unit, Cambridge, UK
| | - James B Rowe
- Department of Clinical Neurosciences, University of Cambridge, UK
- Medical Research Council Cognition and Brain Sciences Unit, Cambridge, UK
| |
Collapse
|
15
|
Waninger S, Berka C, Meghdadi A, Karic MS, Stevens K, Aguero C, Sitnikova T, Salat DH, Verma A. Event-related potentials during sustained attention and memory tasks: Utility as biomarkers for mild cognitive impairment. ALZHEIMER'S & DEMENTIA (AMSTERDAM, NETHERLANDS) 2018; 10:452-460. [PMID: 30263929 PMCID: PMC6156804 DOI: 10.1016/j.dadm.2018.05.007] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
INTRODUCTION The objective of the study is to validate attention and memory tasks that elicit event-related potentials (ERPs) for utility as sensitive biomarkers for early dementia. METHODS A 3-choice vigilance task designed to evaluate sustained attention and standard image recognition memory task designed to evaluate attention, encoding, and image recognition memory were administered with concurrent electroencephalography acquisition to elicit ERPs in mild cognitive impairment (MCI) and healthy cohorts. ERPs were averaged, and mean or maximum amplitude of components was measured and compared between and within cohorts. RESULTS There was significant suppression of the amplitude of the late positive potential in the MCI cohort compared with the healthy controls during 3-choice vigilance task, predominantly over occipital and right temporal-parietal region, and standard image recognition memory task over all regions. During standard image recognition memory task, diminished performance showed strong correlation with electroencephalography measurements. The old/new effects observed in the healthy controls cohort correlated with performance and were lost in MCI. DISCUSSION ERPs obtained during cognitive tasks may provide a powerful tool for assessing MCI and have strong potential as sensitive and robust biomarkers for tracking disease progression and evaluating response to investigative therapeutics.
Collapse
Affiliation(s)
- Shani Waninger
- Advanced Brain Monitoring, Inc., Carlsbad, CA, USA,Corresponding author. Tel.: 760-476-0099; Fax: 760-476-3620.
| | - Chris Berka
- Advanced Brain Monitoring, Inc., Carlsbad, CA, USA
| | | | | | - Kimberly Stevens
- MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, USA
| | - Cinthya Aguero
- MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, USA
| | - Tatiana Sitnikova
- MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, USA
| | - David H. Salat
- MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, USA
| | | |
Collapse
|
16
|
Ochoa JF, Alonso JF, Duque JE, Tobón CA, Mañanas MA, Lopera F, Hernández AM. Successful Object Encoding Induces Increased Directed Connectivity in Presymptomatic Early-Onset Alzheimer's Disease. J Alzheimers Dis 2018; 55:1195-1205. [PMID: 27792014 PMCID: PMC5147495 DOI: 10.3233/jad-160803] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND Recent studies report increases in neural activity in brain regions critical to episodic memory at preclinical stages of Alzheimer's disease (AD). Although electroencephalography (EEG) is widely used in AD studies, given its non-invasiveness and low cost, there is a need to translate the findings in other neuroimaging methods to EEG. OBJECTIVE To examine how the previous findings using functional magnetic resonance imaging (fMRI) at preclinical stage in presenilin-1 E280A mutation carriers could be assessed and extended, using EEG and a connectivity approach. METHODS EEG signals were acquired during resting and encoding in 30 normal cognitive young subjects, from an autosomal dominant early-onset AD kindred from Antioquia, Colombia. Regions of the brain previously reported as hyperactive were used for connectivity analysis. RESULTS Mutation carriers exhibited increasing connectivity at analyzed regions. Among them, the right precuneus exhibited the highest changes in connectivity. CONCLUSION Increased connectivity in hyperactive cerebral regions is seen in individuals, genetically-determined to develop AD, at preclinical stage. The use of a connectivity approach and a widely available neuroimaging technique opens the possibility to increase the use of EEG in early detection of preclinical AD.
Collapse
Affiliation(s)
- John Fredy Ochoa
- Bioinstrumentation and Clinical Engineering Research Group, Bioengineering Program, Universidad de Antioquia UdeA, Calle 70 No. 52-21, Medellín, Colombia
| | - Joan Francesc Alonso
- Department of Automatic Control (ESAII), Biomedical Engineering Research Center (CREB), Universitat Politènica de Catalunya (UPC), Barcelona, Spain.,Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain
| | - Jon Edinson Duque
- Bioinstrumentation and Clinical Engineering Research Group, Bioengineering Program, Universidad de Antioquia UdeA, Calle 70 No. 52-21, Medellín, Colombia
| | - Carlos Andrés Tobón
- Neuroscience Group of Antioquia, Medical School, Universidad de Antioquia UdeA, Calle 70 No. 52-21, Medellín, Colombia.,Neuropsychology and Behavior group, Medical School, Universidad de Antioquia UdeA, Calle 70 No. 52-21, Medellín, Colombia
| | - Miguel Angel Mañanas
- Department of Automatic Control (ESAII), Biomedical Engineering Research Center (CREB), Universitat Politènica de Catalunya (UPC), Barcelona, Spain.,Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain
| | - Francisco Lopera
- Neuroscience Group of Antioquia, Medical School, Universidad de Antioquia UdeA, Calle 70 No. 52-21, Medellín, Colombia
| | - Alher Mauricio Hernández
- Bioinstrumentation and Clinical Engineering Research Group, Bioengineering Program, Universidad de Antioquia UdeA, Calle 70 No. 52-21, Medellín, Colombia
| |
Collapse
|
17
|
Correa-Jaraba KS, Lindín M, Díaz F. Increased Amplitude of the P3a ERP Component as a Neurocognitive Marker for Differentiating Amnestic Subtypes of Mild Cognitive Impairment. Front Aging Neurosci 2018; 10:19. [PMID: 29483869 PMCID: PMC5816051 DOI: 10.3389/fnagi.2018.00019] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2017] [Accepted: 01/16/2018] [Indexed: 01/08/2023] Open
Abstract
The event-related potential (ERP) technique has been shown to be useful for evaluating changes in brain electrical activity associated with different cognitive processes, particularly in Alzheimer's disease (AD). Longitudinal studies have shown that a high proportion of people with amnestic mild cognitive impairment (aMCI) go on to develop AD. aMCI is divided into two subtypes according to the presence of memory impairment only (single-domain aMCI: sdaMCI) or impairment of memory and other cognitive domains (multi-domain aMCI: mdaMCI). The main aim of this study was to examine the effects of sdaMCI and mdaMCI on the P3a ERP component associated with the involuntary orientation of attention toward unattended infrequent novel auditory stimuli. Participants performed an auditory-visual distraction-attention task, in which they were asked to ignore the auditory stimuli (standard, deviant, and novel) and to attend to the visual stimuli (responding to some of them: Go stimuli). P3a was identified in the Novel minus Standard difference waveforms, and reaction times (RTs) and hits (in response to Go stimuli) were also analyzed. Participants were classified into three groups: Control, 20 adults (mean age (M): 65.8 years); sdaMCI, 19 adults (M: 67 years); and mdaMCI, 11 adults (M: 71 years). In all groups, the RTs were significantly longer when Go stimuli were preceded by novel (relative to standard) auditory stimuli, suggesting a distraction effect triggered by novel stimuli; mdaMCI participants made significantly fewer hits than control and sdaMCI participants. P3a comprised two consecutive phases in all groups: early-P3a (e-P3a), which may reflect the orienting response toward the irrelevant stimuli, and late-P3a (l-P3a), which may be a correlate of subsequent evaluation of these stimuli. The e-P3a amplitude was significantly larger in mdaMCI than in sdaMCI participants, and the l-P3a amplitude was significantly larger in mdaMCI than in sdaMCI and Control participants, indicating greater involuntary capture of attention to unattended novel auditory stimuli and allocation of more attentional resources for the subsequent evaluation of these stimuli in mdaMCI participants. The e-P3a and l-P3a components showed moderate to high sensitivity and specificity for distinguishing between groups, suggesting that both may represent optimal neurocognitive markers for differentiating aMCI subtypes.
Collapse
Affiliation(s)
- Kenia S. Correa-Jaraba
- Laboratorio de Psicofisioloxía e Neurociencia Cognitiva, Facultade de Psicoloxía, Universidade de Santiago de Compostela, Galicia, Spain
| | | | | |
Collapse
|
18
|
Penny W, Iglesias-Fuster J, Quiroz YT, Lopera FJ, Bobes MA. Dynamic Causal Modeling of Preclinical Autosomal-Dominant Alzheimer's Disease. J Alzheimers Dis 2018; 65:697-711. [PMID: 29562504 PMCID: PMC6923812 DOI: 10.3233/jad-170405] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/06/2017] [Indexed: 01/13/2023]
Abstract
Dynamic causal modeling (DCM) is a framework for making inferences about changes in brain connectivity using neuroimaging data. We fitted DCMs to high-density EEG data from subjects performing a semantic picture matching task. The subjects are carriers of the PSEN1 mutation, which leads to early onset Alzheimer's disease, but at the time of EEG acquisition in 1999, these subjects were cognitively unimpaired. We asked 1) what is the optimal model architecture for explaining the event-related potentials in this population, 2) which connections are different between this Presymptomatic Carrier (PreC) group and a Non-Carrier (NonC) group performing the same task, and 3) which network connections are predictive of subsequent Mini-Mental State Exam (MMSE) trajectories. We found 1) a model with hierarchical rather than lateral connections between hemispheres to be optimal, 2) that a pathway from right inferotemporal cortex (IT) to left medial temporal lobe (MTL) was preferentially activated by incongruent items for subjects in the PreC group but not the NonC group, and 3) that increased effective connectivity among left MTL, right IT, and right MTL was predictive of subsequent MMSE scores.
Collapse
Affiliation(s)
- Will Penny
- School of Psychology, University of East Anglia, Norwich, UK
- Wellcome Trust Centre for Neuroimaging, University College, London, UK
| | | | - Yakeel T. Quiroz
- Massachusetts General Hospital, Boston, MA, USA
- Group of Neurosciences, Medical School, Universidad de Antioquia, Medellin, Colombia
| | | | - Maria A. Bobes
- Department of Cognitive Neuroscience Cuban Neuroscience Center, Havana, Cuba
- Key Laboratory for Neuroinformation of Ministry of Education, Center for Information in Medicine, University of Electronic Science and Technology of China
| |
Collapse
|
19
|
Maia da Silva MN, Millington RS, Bridge H, James-Galton M, Plant GT. Visual Dysfunction in Posterior Cortical Atrophy. Front Neurol 2017; 8:389. [PMID: 28861031 PMCID: PMC5561011 DOI: 10.3389/fneur.2017.00389] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Accepted: 07/21/2017] [Indexed: 01/08/2023] Open
Abstract
Posterior cortical atrophy (PCA) is a syndromic diagnosis. It is characterized by progressive impairment of higher (cortical) visual function with imaging evidence of degeneration affecting the occipital, parietal, and posterior temporal lobes bilaterally. Most cases will prove to have Alzheimer pathology. The aim of this review is to summarize the development of the concept of this disorder since it was first introduced. A critical discussion of the evolving diagnostic criteria is presented and the differential diagnosis with regard to the underlying pathology is reviewed. Emphasis is given to the visual dysfunction that defines the disorder, and the classical deficits, such as simultanagnosia and visual agnosia, as well as the more recently recognized visual field defects, are reviewed, along with the evidence on their neural correlates. The latest developments on the imaging of PCA are summarized, with special attention to its role on the differential diagnosis with related conditions.
Collapse
Affiliation(s)
- Mari N Maia da Silva
- The National Hospital for Neurology and Neurosurgery, London, United Kingdom.,Cognitive and Behavioural Neurology Unit, Hospital das Clínicas, University of São Paulo, São Paulo, Brazil
| | - Rebecca S Millington
- Oxford Centre for fMRI of the Brain (FMRIB), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom
| | - Holly Bridge
- Oxford Centre for fMRI of the Brain (FMRIB), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom
| | - Merle James-Galton
- The National Hospital for Neurology and Neurosurgery, London, United Kingdom
| | - Gordon T Plant
- The National Hospital for Neurology and Neurosurgery, London, United Kingdom.,Moorfields Eye Hospital, London, United Kingdom.,St. Thomas' Hospital, London, United Kingdom
| |
Collapse
|
20
|
Gao Y, Cheung RTF, Gao J, Lau EYY, Wan JHY, Mok MY. Electrophysiological Study on Cognitive Function in Systemic Lupus Erythematosus Patients With Previous Neuropsychiatric Involvement. Clin EEG Neurosci 2017; 48:251-258. [PMID: 27468748 DOI: 10.1177/1550059416660956] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
This study aimed to evaluate P300 as an electrophysiological marker of cognitive function in patients with systemic lupus erythematosus (SLE) who had previous neuropsychiatric (NPSLE) involvement and were diagnosed to have cognitive impairment by standard neuropsychological tests. Event-related potentials (ERPs) were assessed by the auditory and visual oddball paradigms. Amplitude and latency of P300 at the frontal (Fz), central (Cz), and parietal (Pz) regions were determined and compared with controls. P300 detection was performed in NPSLE patients with pre-diagnosed cognitive impairment (n = 9), matched SLE patients without previous NPSLE (non-NPSLE) (n = 9), and healthy controls (n = 15). Auditory oddball task did not show any P300 abnormality between groups. Visual oddball task revealed reduced amplitude of P300 over Fz ( P = .002) and Cz ( P = .009) electrodes in NPSLE patients compared with healthy controls and among those who had predominant memory deficit ( P = .01 at Fz). Abnormal P300 was also observed in non-NPSLE patients at Fz and Cz. Using visual oddball paradigm, abnormal P300 was found in NPSLE patients over frontal and parietal regions compared with normal controls but was not discriminative from possible subclinical disease in non-NPSLE patients. In conclusion, visual oddball paradigm was a more sensitive electrophysiological marker than auditory oddball paradigm for cognitive impairment in NPSLE patients.
Collapse
Affiliation(s)
- Yang Gao
- 1 Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong SAR
| | - Raymond Tak Fai Cheung
- 1 Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong SAR
| | - Junling Gao
- 1 Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong SAR
| | - Esther Y Y Lau
- 2 Department of Psychology, the University of Hong Kong, Hong Kong SAR
| | - Jacky Ho Yin Wan
- 2 Department of Psychology, the University of Hong Kong, Hong Kong SAR
| | - Mo Yin Mok
- 1 Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong SAR.,3 Department of Biomedical Sciences, the City University of Hong Kong, Hong Kong SAR
| |
Collapse
|
21
|
Ochoa JF, Alonso JF, Duque JE, Tobón CA, Baena A, Lopera F, Mañanas MA, Hernández AM. Precuneus Failures in Subjects of the PSEN1 E280A Family at Risk of Developing Alzheimer's Disease Detected Using Quantitative Electroencephalography. J Alzheimers Dis 2017; 58:1229-1244. [PMID: 28550254 DOI: 10.3233/jad-161291] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Presenilin-1 (PSEN1) mutations are the most common cause of familial early onset Alzheimer's disease (AD). The PSEN1 E280A (E280A) mutation has an autosomal dominant inheritance and is involved in the production of amyloid-β. The largest family group of carriers with E280A mutation is found in Antioquia, Colombia. The study of mutation carriers provides a unique opportunity to identify brain changes in stages previous to AD. Electroencephalography (EEG) is a low cost and minimally invasiveness technique that enables the following of brain changes in AD. OBJECTIVE To examine how previous reported differences in EEG for Theta and Alpha-2 rhythms in E280A subjects are related to specific regions in cortex and could be tracked across different ages. METHODS EEG signals were acquired during resting state from non-carriers and carriers, asymptomatic and symptomatic subjects from E280A kindred from Antioquia, Colombia. Independent component analysis (ICA) and inverse solution methods were used to locate brain regions related to differences in Theta and Alpha-2 bands. RESULTS ICA identified two components, mainly related to the Precuneus, where the differences in Theta and Alpha-2 exist simultaneously at asymptomatic and symptomatic stages. When the ratio between Theta and Alpha-2 is used, significant correlations exist with age and a composite cognitive scale. CONCLUSION Theta and Alpha-2 rhythms are altered in E280A subjects. The alterations are possible to track at Precuneus regions using EEG, ICA, and inverse solution methods.
Collapse
Affiliation(s)
- John Fredy Ochoa
- Bioinstrumentation and Clinical Engineering Research Group, Bioengineering Program, Universidad de Antioquia, Medellín, Colombia
| | - Joan Francesc Alonso
- Department of Automatic Control (ESAII), Biomedical Engineering Research Center (CREB), Universitat Politènica de Catalunya (UPC), Barcelona, Spain.,Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain
| | - Jon Edinson Duque
- Bioinstrumentation and Clinical Engineering Research Group, Bioengineering Program, Universidad de Antioquia, Medellín, Colombia
| | - Carlos Andrés Tobón
- Neuroscience Group of Antioquia, Medical School, Universidad de Antioquia, Medellín, Colombia.,Neuropsychology and Behavior Group, Medical School, Universidad de Antioquia, Medellín, Colombia
| | - Ana Baena
- Neuroscience Group of Antioquia, Medical School, Universidad de Antioquia, Medellín, Colombia
| | - Francisco Lopera
- Neuroscience Group of Antioquia, Medical School, Universidad de Antioquia, Medellín, Colombia
| | - Miguel Angel Mañanas
- Department of Automatic Control (ESAII), Biomedical Engineering Research Center (CREB), Universitat Politènica de Catalunya (UPC), Barcelona, Spain.,Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain
| | - Alher Mauricio Hernández
- Bioinstrumentation and Clinical Engineering Research Group, Bioengineering Program, Universidad de Antioquia, Medellín, Colombia
| |
Collapse
|
22
|
Bennys K, Gabelle A, Berr C, De Verbizier D, Andrieu S, Vellas B, Touchon J. Cognitive Event-Related Potential, an Early Diagnosis Biomarker in Frail Elderly Subjects: The ERP-MAPT-PLUS Ancillary Study. J Alzheimers Dis 2017; 58:87-97. [DOI: 10.3233/jad-161012] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- Karim Bennys
- Memory Research and Resource Center for Alzheimer’s Disease, Department of Neurology, University Hospital of Montpellier, Montpellier, France
- Clinical Neurophysiology Unit, Department of Neurology, University Hospital of Montpellier, France
| | - Audrey Gabelle
- Memory Research and Resource Center for Alzheimer’s Disease, Department of Neurology, University Hospital of Montpellier, Montpellier, France
- INSERM U1183, University of Montpellier, France
| | | | - Delphine De Verbizier
- Department of Nuclear Medicine, Gui de Chauliac University Hospital, Montpellier, France
| | - Sandrine Andrieu
- Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France
- INSERM UMR 1027, Toulouse, France
- University of Toulouse III, Toulouse, France
- Department of Epidemiology and Public Health, CHU Toulouse, Toulouse, France
| | - Bruno Vellas
- Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France
- INSERM UMR 1027, Toulouse, France
- University of Toulouse III, Toulouse, France
| | - Jacques Touchon
- Memory Research and Resource Center for Alzheimer’s Disease, Department of Neurology, University Hospital of Montpellier, Montpellier, France
- INSERM U1061, University of Montpellier, France
| | | |
Collapse
|
23
|
Li J, Broster LS, Jicha GA, Munro NB, Schmitt FA, Abner E, Kryscio R, Smith CD, Jiang Y. A cognitive electrophysiological signature differentiates amnestic mild cognitive impairment from normal aging. ALZHEIMERS RESEARCH & THERAPY 2017; 9:3. [PMID: 28100252 PMCID: PMC5244569 DOI: 10.1186/s13195-016-0229-3] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/14/2016] [Accepted: 12/08/2016] [Indexed: 12/19/2022]
Abstract
Background Noninvasive and effective biomarkers for early detection of amnestic mild cognitive impairment (aMCI) before measurable changes in behavioral performance remain scarce. Cognitive event-related potentials (ERPs) measure synchronized synaptic neural activity associated with a cognitive event. Loss of synapses is a hallmark of the neuropathology of early Alzheimer’s disease (AD). In the present study, we tested the hypothesis that ERP responses during working memory retrieval discriminate aMCI from cognitively normal controls (NC) matched in age and education. Methods Eighteen NC, 17 subjects with aMCI, and 13 subjects with AD performed a delayed match-to-sample task specially designed not only to be easy enough for impaired participants to complete but also to generate comparable performance between subjects with NC and those with aMCI. Scalp electroencephalography, memory accuracy, and reaction times were measured. Results Whereas memory performance separated the AD group from the others, the performance of NC and subjects with aMCI was similar. In contrast, left frontal cognitive ERP patterns differentiated subjects with aMCI from NC. Enhanced P3 responses at left frontal sites were associated with nonmatching relative to matching stimuli during working memory tasks in patients with aMCI and AD, but not in NC. The accuracy of discriminating aMCI from NC was 85% by using left frontal match/nonmatch effect combined with nonmatch reaction time. Conclusions The left frontal cognitive ERP indicator holds promise as a sensitive, simple, affordable, and noninvasive biomarker for detection of early cognitive impairment.
Collapse
Affiliation(s)
- Juan Li
- CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, 100101, Beijing, China. .,Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, KY, 40536, USA.
| | - Lucas S Broster
- Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, KY, 40536, USA
| | - Gregory A Jicha
- Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, 40536, USA.,Department of Neurology, University of Kentucky College of Medicine, Lexington, KY, 40536, USA
| | | | - Frederick A Schmitt
- Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, KY, 40536, USA.,Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, 40536, USA.,Department of Neurology, University of Kentucky College of Medicine, Lexington, KY, 40536, USA
| | - Erin Abner
- Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, 40536, USA.,Department of Epidemiology, University of Kentucky College of Public Health, Lexington, KY, 40536, USA
| | - Richard Kryscio
- Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, 40536, USA.,Department of Statistics, University of Kentucky, Lexington, KY, 40536, USA.,Department of Biostatistics, University of Kentucky College of Public Health, Lexington, KY, 40536, USA
| | - Charles D Smith
- Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, 40536, USA.,Department of Neurology, University of Kentucky College of Medicine, Lexington, KY, 40536, USA
| | - Yang Jiang
- Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, KY, 40536, USA. .,Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, 40536, USA.
| |
Collapse
|
24
|
Pietto M, Parra MA, Trujillo N, Flores F, García AM, Bustin J, Richly P, Manes F, Lopera F, Ibáñez A, Baez S. Behavioral and Electrophysiological Correlates of Memory Binding Deficits in Patients at Different Risk Levels for Alzheimer’s Disease. J Alzheimers Dis 2016; 53:1325-40. [DOI: 10.3233/jad-160056] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Marcos Pietto
- Instituto de Neurociencia Cognitiva y Traslacional (INCyT), Laboratorio de Psicología Experimental y Neurociencias (LPEN), Fundación INECO, Universidad de Favaloro, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
- Unidad de Neurobiología Aplicada, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (CEMIC), Consejo Nacional de Investigaciones Científicas y Técnicas CONICET, Buenos Aires, Argentina
| | - Mario A. Parra
- School of Life Sciences, Psychology, Heriot-Watt University, UK
- Human Cognitive Neuroscience and Centre for Cognitive Ageing and Cognitive Epidemiology, Department of Psychology, University of Edinburgh, UK
- Alzheimer Scotland Dementia Research Centre and Scottish Dementia Clinical Research Network, UK
- Universidad Autónoma del Caribe, Barranquilla, Colombia
| | - Natalia Trujillo
- School of Public Health, University of Antioquia (UDEA), Medellin, Colombia
- Neuroscience Group, Faculty of Medicine, University of Antioquia (UDEA), Medellin
| | - Facundo Flores
- Instituto de Neurociencia Cognitiva y Traslacional (INCyT), Laboratorio de Psicología Experimental y Neurociencias (LPEN), Fundación INECO, Universidad de Favaloro, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Adolfo M. García
- Instituto de Neurociencia Cognitiva y Traslacional (INCyT), Laboratorio de Psicología Experimental y Neurociencias (LPEN), Fundación INECO, Universidad de Favaloro, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
- ACR Centre of Excellence in Cognition and its Disorders, Macquarie University, Sydney, Australia
| | - Julian Bustin
- Instituto de Neurociencia Cognitiva y Traslacional (INCyT), Laboratorio de Psicología Experimental y Neurociencias (LPEN), Fundación INECO, Universidad de Favaloro, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Pablo Richly
- Instituto de Neurociencia Cognitiva y Traslacional (INCyT), Laboratorio de Psicología Experimental y Neurociencias (LPEN), Fundación INECO, Universidad de Favaloro, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Facundo Manes
- Instituto de Neurociencia Cognitiva y Traslacional (INCyT), Laboratorio de Psicología Experimental y Neurociencias (LPEN), Fundación INECO, Universidad de Favaloro, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
- Faculty of Elementary and Special Education (FEEyE), National University of Cuyo (UNCuyo), Sobremonte 74, C5500, Mendoza, Argentina
| | - Francisco Lopera
- Neuroscience Group, Faculty of Medicine, University of Antioquia (UDEA), Medellin
| | - Agustín Ibáñez
- Instituto de Neurociencia Cognitiva y Traslacional (INCyT), Laboratorio de Psicología Experimental y Neurociencias (LPEN), Fundación INECO, Universidad de Favaloro, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
- Universidad Autónoma del Caribe, Barranquilla, Colombia
- Faculty of Elementary and Special Education (FEEyE), National University of Cuyo (UNCuyo), Sobremonte 74, C5500, Mendoza, Argentina
| | - Sandra Baez
- Instituto de Neurociencia Cognitiva y Traslacional (INCyT), Laboratorio de Psicología Experimental y Neurociencias (LPEN), Fundación INECO, Universidad de Favaloro, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
- Grupo de Investigación Cerebro y Cognición Social, Bogotá, Colombia
| |
Collapse
|
25
|
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, Epelbaum S, Frisoni GB, Gauthier S, Genthon R, Gouw AA, Habert MO, Holtzman DM, Kivipelto M, Lista S, Molinuevo JL, O'Bryant SE, Rabinovici GD, Rowe C, Salloway S, Schneider LS, Sperling R, Teichmann M, Carrillo MC, Cummings J, Jack CR. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement 2016; 12:292-323. [PMID: 27012484 PMCID: PMC6417794 DOI: 10.1016/j.jalz.2016.02.002] [Citation(s) in RCA: 1162] [Impact Index Per Article: 145.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this "silent" stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.
Collapse
Affiliation(s)
- Bruno Dubois
- Institute of Memory and Alzheimer's Disease (IM2A) and Brain and Spine Institute (ICM) UMR S 1127 Frontlab, Department of Neurology, AP_HP, Pitié-Salpêtrière University Hospital, Sorbonne Universities, Pierre et Marie Curie University, Paris 06, Paris, France.
| | - Harald Hampel
- Institute of Memory and Alzheimer's Disease (IM2A) and Brain and Spine Institute (ICM) UMR S 1127 Frontlab, Department of Neurology, AP_HP, Pitié-Salpêtrière University Hospital, Sorbonne Universities, Pierre et Marie Curie University, Paris 06, Paris, France; AXA Research Fund & UPMC Chair, Paris, France
| | | | - Philip Scheltens
- Department of Neurology and Alzheimer Center, VU University Medical Center and Neuroscience Campus, Amsterdam, The Netherlands
| | - Paul Aisen
- University of Southern California San Diego, CA, USA
| | - Sandrine Andrieu
- UMR1027, INSERM, Université Toulouse III, Toulouse University Hospital, France
| | - Hovagim Bakardjian
- IHU-A-ICM-Institut des Neurosciences translationnelles de Paris, Paris, France
| | - Habib Benali
- INSERM U1146-CNRS UMR 7371-UPMC UM CR2, Site Pitié-Salpêtrière, Paris, France
| | - Lars Bertram
- Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), Institutes of Neurogenetics and Integrative and Experimental Genomics, University of Lübeck, Lübeck, Germany; School of Public Health, Faculty of Medicine, Imperial College London, London, UK
| | - Kaj Blennow
- Clinical Neurochemistry Lab, Department of Neuroscience and Physiology, University of Gothenburg, Mölndal Hospital, Sahlgrenska University Hospital, Mölndal, Sweden
| | - Karl Broich
- Federal Institute for Drugs and Medical Devices, Bonn, Germany
| | - Enrica Cavedo
- AXA Research Fund & UPMC Chair, Paris, France; Laboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Sebastian Crutch
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, University College London, London, UK
| | | | - Charles Duyckaerts
- University Pierre et Marie Curie, Assistance Publique des Hôpitaux de Paris, Alzheimer-Prion Team Institut du Cerveau et de la Moelle (ICM), Paris, France
| | - Stéphane Epelbaum
- Institute of Memory and Alzheimer's Disease (IM2A) and Brain and Spine Institute (ICM) UMR S 1127 Frontlab, Department of Neurology, AP_HP, Pitié-Salpêtrière University Hospital, Sorbonne Universities, Pierre et Marie Curie University, Paris 06, Paris, France
| | - Giovanni B Frisoni
- University Hospitals and University of Geneva, Geneva, Switzerland; IRCCS Fatebenefratelli, Brescia, Italy
| | - Serge Gauthier
- McGill Center for Studies in Aging, Douglas Mental Health Research Institute, Montreal, Canada
| | - Remy Genthon
- Fondation pour la Recherche sur Alzheimer, Hôpital Pitié-Salpêtrière, Paris, France
| | - Alida A Gouw
- UMR1027, INSERM, Université Toulouse III, Toulouse University Hospital, France; Department of Clinical Neurophysiology/MEG Center, VU University Medical Center, Amsterdam
| | - Marie-Odile Habert
- Sorbonne Universités, UPMC Univ Paris 06, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Département de Médecine Nucléaire, Paris, France
| | - David M Holtzman
- Department of Neurology, Washington University, Hope Center for Neurological Disorders, St. Louis, MO, USA; Department of Neurology, Washington University, Knight Alzheimer's Disease Research Center, St. Louis, MO, USA
| | - Miia Kivipelto
- Center for Alzheimer Research, Karolinska Institutet, Department of Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden; Institute of Clinical Medicine/ Neurology, University of Eastern Finland, Kuopio, Finland
| | | | - José-Luis Molinuevo
- Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain
| | - Sid E O'Bryant
- Center for Alzheimer's & Neurodegenerative Disease Research, University of North Texas Health Science Center, TX, USA
| | - Gil D Rabinovici
- Memory & Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA
| | - Christopher Rowe
- Department of Molecular Imaging, Austin Health, University of Melbourne, Australia
| | - Stephen Salloway
- Memory and Aging Program, Butler Hospital, Alpert Medical School of Brown University, USA; Department of Neurology, Alpert Medical School of Brown University, USA; Department of Psychiatry, Alpert Medical School of Brown University, USA
| | - Lon S Schneider
- Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA
| | - Reisa Sperling
- Harvard Medical School, Memory Disorders Unit, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, USA; Harvard Medical School, Memory Disorders Unit, Center for Alzheimer Research and Treatment, Massachusetts General Hospital, Boston, USA
| | - Marc Teichmann
- Institute of Memory and Alzheimer's Disease (IM2A) and Brain and Spine Institute (ICM) UMR S 1127 Frontlab, Department of Neurology, AP_HP, Pitié-Salpêtrière University Hospital, Sorbonne Universities, Pierre et Marie Curie University, Paris 06, Paris, France
| | - Maria C Carrillo
- The Alzheimer's Association Division of Medical & Scientific Relations, Chicago, USA
| | - Jeffrey Cummings
- Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
| | - Cliff R Jack
- Department of Radiology, Mayo Clinic, Rochester MN, USA
| |
Collapse
|
26
|
Cecchi M, Moore DK, Sadowsky CH, Solomon PR, Doraiswamy PM, Smith CD, Jicha GA, Budson AE, Arnold SE, Fadem KC. A clinical trial to validate event-related potential markers of Alzheimer's disease in outpatient settings. ALZHEIMER'S & DEMENTIA (AMSTERDAM, NETHERLANDS) 2015; 1:387-94. [PMID: 27239520 PMCID: PMC4879492 DOI: 10.1016/j.dadm.2015.08.004] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
INTRODUCTION We investigated whether event-related potentials (ERP) collected in outpatient settings and analyzed with standardized methods can provide a sensitive and reliable measure of the cognitive deficits associated with early Alzheimer's disease (AD). METHODS A total of 103 subjects with probable mild AD and 101 healthy controls were recruited at seven clinical study sites. Subjects were tested using an auditory oddball ERP paradigm. RESULTS Subjects with mild AD showed lower amplitude and increased latency for ERP features associated with attention, working memory, and executive function. These subjects also had decreased accuracy and longer reaction time in the target detection task associated with the ERP test. DISCUSSION Analysis of ERP data showed significant changes in subjects with mild AD that are consistent with the cognitive deficits found in this population. The use of an integrated hardware/software system for data acquisition and automated data analysis methods make administration of ERP tests practical in outpatient settings.
Collapse
Affiliation(s)
| | | | - Carl H. Sadowsky
- Department of Neurology, Nova Southeastern University, Fort Lauderdale, FL, USA
| | - Paul R. Solomon
- Department of Psychology, Williams College, Williamstown, MA, USA
| | - P. Murali Doraiswamy
- Departments of Psychiatry and Medicine, Duke Medicine and Duke Institute for Brain Sciences, Durham, NC, USA
| | - Charles D. Smith
- Department of Neurology, University of Kentucky, Lexington, KY, USA
| | - Gregory A. Jicha
- Department of Neurology, University of Kentucky, Lexington, KY, USA
| | - Andrew E. Budson
- Department of Cognitive & Behavioral Neurology, VA Boston Healthcare System, Boston, MA, USA
| | - Steven E. Arnold
- Departments of Psychiatry and Neurology, University of Pennsylvania, Philadelphia, PA, USA
| | | |
Collapse
|
27
|
Quiroz YT, Schultz AP, Chen K, Protas HD, Brickhouse M, Fleisher AS, Langbaum JB, Thiyyagura P, Fagan AM, Shah AR, Muniz M, Arboleda-Velasquez JF, Munoz C, Garcia G, Acosta-Baena N, Giraldo M, Tirado V, Ramírez DL, Tariot PN, Dickerson BC, Sperling RA, Lopera F, Reiman EM. Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease: A Cross-Sectional Study. JAMA Neurol 2015; 72:912-9. [PMID: 26121081 DOI: 10.1001/jamaneurol.2015.1099] [Citation(s) in RCA: 79] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
IMPORTANCE Brain imaging and fluid biomarkers are characterized in children at risk for autosomal dominant Alzheimer disease (ADAD). OBJECTIVE To characterize and compare structural magnetic resonance imaging (MRI), resting-state and task-dependent functional MRI, and plasma amyloid-β (Aβ) measurements in presenilin 1 (PSEN1) E280A mutation-carrying and noncarrying children with ADAD. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional measures of structural and functional MRI and plasma Aβ assays were assessed in 18 PSEN1 E280A carriers and 19 noncarriers aged 9 to 17 years from a Colombian kindred with ADAD. Recruitment and data collection for this study were conducted at the University of Antioquia and the Hospital Pablo Tobon Uribe in Medellín, Colombia, between August 2011 and June 2012. MAIN OUTCOMES AND MEASURES All participants had blood sampling, structural MRI, and functional MRI during associative memory encoding and resting-state and cognitive assessments. Outcome measures included plasma Aβ1-42 concentrations and Aβ1-42:Aβ1-40 ratios, memory encoding-dependent activation changes, resting-state connectivity, and regional gray matter volumes. Structural and functional MRI data were compared using automated brain mapping algorithms and search regions related to AD. RESULTS Similar to findings in adult mutation carriers, in the later preclinical and clinical stages of ADAD, mutation-carrying children were distinguished from control individuals by significantly higher plasma Aβ1-42 levels (mean [SD]: carriers, 18.8 [5.1] pg/mL and noncarriers, 13.1 [3.2] pg/mL; P < .001) and Aβ1-42:Aβ1-40 ratios (mean [SD]: carriers, 0.32 [0.06] and noncarriers, 0.21 [0.03]; P < .001), as well as less memory encoding task-related deactivation in parietal regions (eg, mean [SD] parameter estimates for the right precuneus were -0.590 [0.50] for noncarriers and -0.087 [0.38] for carriers; P < .005 uncorrected). Unlike carriers in the later stages, mutation-carrying children demonstrated increased functional connectivity of the posterior cingulate cortex with medial temporal lobe regions (mean [SD] parameter estimates were 0.038 [0.070] for noncarriers and 0.190 [0.057] for carriers), as well as greater gray matter volumes in temporal regions (eg, left parahippocampus; P < . 049, corrected for multiple comparisons). CONCLUSIONS AND RELEVANCE Children at genetic risk for ADAD have functional and structural brain changes and abnormal levels of plasma Aβ1-42. The extent to which the underlying brain changes are either neurodegenerative or developmental remains to be determined. This study provides additional information about the earliest known biomarker changes associated with ADAD.
Collapse
Affiliation(s)
- Yakeel T Quiroz
- Department of Neurology, Massachusetts General Hospital, Boston2Department of Psychiatry, Massachusetts General Hospital, Boston3Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston4Harvard Medical School, Boston, Ma
| | - Aaron P Schultz
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston4Harvard Medical School, Boston, Massachusetts
| | - Kewei Chen
- Banner Alzheimer's Institute, Phoenix, Arizona7Arizona Alzheimer's Consortium, Phoenix8Department of Mathematics and Statistics, Arizona State University, Tempe
| | - Hillary D Protas
- Banner Alzheimer's Institute, Phoenix, Arizona7Arizona Alzheimer's Consortium, Phoenix
| | - Michael Brickhouse
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston4Harvard Medical School, Boston, Massachusetts9Frontotemporal Dementia Unit, Department of Neurology, Massachusetts General Hospital, Boston
| | - Adam S Fleisher
- Banner Alzheimer's Institute, Phoenix, Arizona10Eli Lilly and Company, Indianapolis, Indiana11Department of Neurosciences, University of California, San Diego
| | - Jessica B Langbaum
- Banner Alzheimer's Institute, Phoenix, Arizona7Arizona Alzheimer's Consortium, Phoenix
| | - Pradeep Thiyyagura
- Banner Alzheimer's Institute, Phoenix, Arizona7Arizona Alzheimer's Consortium, Phoenix
| | - Anne M Fagan
- Department of Neurology, Washington University School of Medicine, St Louis, Missouri
| | - Aarti R Shah
- Department of Neurology, Washington University School of Medicine, St Louis, Missouri
| | - Martha Muniz
- Psychology Department, Boston University, Boston, Massachusetts
| | - Joseph F Arboleda-Velasquez
- Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston15Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts
| | - Claudia Munoz
- Grupo de Neurociencias, Universidad de Antioquia, Medellín, Colombia
| | - Gloria Garcia
- Grupo de Neurociencias, Universidad de Antioquia, Medellín, Colombia
| | | | - Margarita Giraldo
- Grupo de Neurociencias, Universidad de Antioquia, Medellín, Colombia
| | - Victoria Tirado
- Grupo de Neurociencias, Universidad de Antioquia, Medellín, Colombia
| | - Dora L Ramírez
- Grupo de Neurociencias, Universidad de Antioquia, Medellín, Colombia
| | - Pierre N Tariot
- Banner Alzheimer's Institute, Phoenix, Arizona7Arizona Alzheimer's Consortium, Phoenix16Department of Psychiatry, University of Arizona, Phoenix
| | - Bradford C Dickerson
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston4Harvard Medical School, Boston, Massachusetts9Frontotemporal Dementia Unit, Department of Neurology, Massachusetts General Hospital, Boston
| | - Reisa A Sperling
- Department of Neurology, Massachusetts General Hospital, Boston3Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston4Harvard Medical School, Boston, Massachusetts17Center for Alzheimer Research and Treatment, Departm
| | - Francisco Lopera
- Grupo de Neurociencias, Universidad de Antioquia, Medellín, Colombia
| | - Eric M Reiman
- Banner Alzheimer's Institute, Phoenix, Arizona7Arizona Alzheimer's Consortium, Phoenix16Department of Psychiatry, University of Arizona, Phoenix18Division of Neurogenomics, Translational Genomics Research Institute, Phoenix, Arizona
| |
Collapse
|
28
|
Zhang FF, Li J. Inhibitory effect of chloroquine derivatives on presenilin 1 and ubiquilin 1 expression in Alzheimer's disease. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2015; 8:7640-7643. [PMID: 26261684 PMCID: PMC4526018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 04/18/2015] [Accepted: 05/29/2015] [Indexed: 06/04/2023]
Abstract
Alzheimer's disease is the common cause of dementia characterized by the accumulation of amyloid-β produced by breakage of amyloid-β precursor protein (APP). The present study was designed to synthesize and investigate the effect of chloroquine derivatives on the expression of presenilin. Among the five chloroquine derivatives (D1, D2, D3, D4 and D5) synthesized, D5 with diisopropyl substitution was found to be most effect. The results from western blot analysis showed the inhibition of presenilin 1 protein expression on treatment with chloroquine derivative D5 in Daudi cells. The results were also confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR). It was observed that chloroquine derivative D5 downregulates presenilin expression via the inhibition of ubiquilin 1 expression. Thus our study demonstrates that chloroquine derivative D5 treatment can have preventive against Alzheimer's disease.
Collapse
Affiliation(s)
- Fang-Fang Zhang
- Department of Neurology, Xinxiang Central Hospital Xinxiang 453000, China
| | - Jing Li
- Department of Neurology, Xinxiang Central Hospital Xinxiang 453000, China
| |
Collapse
|
29
|
Assessing cognition and function in Alzheimer's disease clinical trials: do we have the right tools? Alzheimers Dement 2014; 10:853-60. [PMID: 25458309 DOI: 10.1016/j.jalz.2014.07.158] [Citation(s) in RCA: 65] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2014] [Accepted: 07/12/2014] [Indexed: 11/23/2022]
Abstract
Several lines of evidence from Alzheimer's disease (AD) research continue to support the notion that the biological changes associated with AD are occurring possibly several decades before an individual will experience the cognitive and functional changes associated with the disease. The National Institute on Aging-Alzheimer's Association revised criteria for AD provided a framework for this new thinking. As a result of this growing understanding, several research efforts have launched or will be launching large secondary prevention trials in AD. These and other efforts have clearly demonstrated a need for better measures of cognitive and functional change in people with the earliest changes associated with AD. Recent draft guidance from the US Food and Drug Administration further elevated the importance of cognitive and functional assessments in early stage clinical trials by proposing that even in the pre-symptomatic stages of the disease, approval will be contingent on demonstrating clinical meaningfulness. The Alzheimer's Association's Research Roundtable addressed these issues at its fall meeting October 28-29, 2013, in Washington, D.C. The focus of the discussion included the need for improved cognitive and functional outcome measures for clinical of participants with preclinical AD and those diagnosed with Mild Cognitive Impairment due to AD.
Collapse
|
30
|
Quiroz YT, Stern CE, Reiman EM, Brickhouse M, Ruiz A, Sperling RA, Lopera F, Dickerson BC. Cortical atrophy in presymptomatic Alzheimer's disease presenilin 1 mutation carriers. J Neurol Neurosurg Psychiatry 2013; 84:556-61. [PMID: 23134660 PMCID: PMC3632663 DOI: 10.1136/jnnp-2012-303299] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Sporadic late-onset Alzheimer's disease (AD) dementia has been associated with a 'signature' of cortical atrophy in paralimbic and heteromodal association regions measured with MRI. OBJECTIVE To investigate whether a similar pattern of cortical atrophy is present in presymptomatic presenilin 1 E280A mutation carriers an average of 6 years before clinical symptom onset. METHODS 40 cognitively normal volunteers from a Colombian population with familial AD were included; 18 were positive for the AD-associated presenilin 1 mutation (carriers, mean age=38) whereas 22 were non-carriers. T1-weighted volumetric MRI images were acquired and cortical thickness was measured. A priori regions of interest from our previous work were used to obtain thickness from AD-signature regions. RESULTS Compared to non-carriers, presymptomatic presenilin 1 mutation carriers exhibited thinner cortex within the AD-signature summary measure (p<0.008). Analyses of individual regions demonstrated thinner angular gyrus, precuneus and superior parietal lobule in carriers compared to non-carriers, with trend-level effects in the medial temporal lobe. CONCLUSION Results demonstrate that cognitively normal individuals genetically determined to develop AD have a thinner cerebral cortex than non-carriers in regions known to be affected by typical late-onset sporadic AD. These findings provide further support for the hypothesis that cortical atrophy is present in preclinical AD more than 5 years prior to symptom onset. Further research is needed to determine whether this method could be used to characterise the age-dependent trajectory of cortical atrophy in presymptomatic stages of AD.
Collapse
Affiliation(s)
- Yakeel T Quiroz
- Psychology Department, Center for Memory and Brain, Boston University, Boston, Massachusetts, USA
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Using pictures and words to understand recognition memory deterioration in amnestic mild cognitive impairment and Alzheimer's disease: a review. Curr Neurol Neurosci Rep 2013; 12:687-94. [PMID: 22927024 DOI: 10.1007/s11910-012-0310-7] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Difficulty recognizing previously encountered stimuli is one of the earliest signs of incipient Alzheimer's disease (AD). Work over the last 10 years has focused on how patients with AD and those in the prodromal stage of amnestic mild cognitive impairment make recognition decisions for visual and verbal stimuli. Interestingly, both groups of patients demonstrate markedly better memory for pictures over words, to a degree that is significantly greater in magnitude than their healthy older counterparts. Understanding this phenomenon not only helps to conceptualize how memory breaks down in AD, but also potentially provides the basis for future interventions. This review critically examines recent recognition memory work using pictures and words in the context of the dual-process theory of recognition and current hypotheses of cognitive breakdown in the course of very early AD.
Collapse
|
32
|
Braverman ER, Blum K, Damle UJ, Kerner M, Dushaj K, Oscar-Berman M. Evoked potentials and neuropsychological tests validate Positron Emission Topography (PET) brain metabolism in cognitively impaired patients. PLoS One 2013; 8:e55398. [PMID: 23526928 PMCID: PMC3604004 DOI: 10.1371/journal.pone.0055398] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2012] [Accepted: 12/27/2012] [Indexed: 01/15/2023] Open
Abstract
Fluorodeoxyglucose (FDG) Positron Emission Topography (PET) brain hypometabolism (HM) correlates with diminished cognitive capacity and risk of developing dementia. However, because clinical utility of PET is limited by cost, we sought to determine whether a less costly electrophysiological measure, the P300 evoked potential, in combination with neuropsychological test performance, would validate PET HM in neuropsychiatric patients. We found that patients with amnestic and non-amnestic cognitive impairment and HM (n = 43) evidenced significantly reduced P300 amplitudes, delayed latencies, and neuropsychological deficits, compared to patients with normal brain metabolism (NM; n = 187). Data from patients with missing cognitive test scores (n = 57) were removed from the final sample, and logistic regression modeling was performed on the modified sample (n = 173, p = .000004). The logistic regression modeling, based on P300 and neuropsychological measures, was used to validate membership in the HM vs. NM groups. It showed classification validation in 13/25 HM subjects (52.0%) and in 125/148 NM subjects (84.5%), correlating with total classification accuracy of 79.8%. In this paper, abnormal P300 evoked potentials coupled with cognitive test impairment validates brain metabolism and mild/moderate cognitive impairment (MCI). To this end, we cautiously propose incorporating electrophysiological and neuropsychological assessments as cost-effective brain metabolism and MCI indicators in primary care. Final interpretation of these results must await required additional studies confirming these interesting results.
Collapse
Affiliation(s)
- Eric R Braverman
- Department of Clinical Neurology, PATH Foundation NY, New York, New York, United States of America.
| | | | | | | | | | | |
Collapse
|
33
|
Biomarkers in Alzheimer's disease with a special emphasis on event-related oscillatory responses. APPLICATION OF BRAIN OSCILLATIONS IN NEUROPSYCHIATRIC DISEASES - SELECTED PAPERS FROM “BRAIN OSCILLATIONS IN COGNITIVE IMPAIRMENT AND NEUROTRANSMITTERS” CONFERENCE, ISTANBUL, TURKEY, 29 APRIL–1 MAY 2011 2013; 62:237-73. [DOI: 10.1016/b978-0-7020-5307-8.00020-x] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
34
|
Quiroz YT, Lopera F, Budson AE. Charting the path for early diagnosis and prevention of Alzheimer's disease. Expert Rev Neurother 2012; 11:1665-7. [PMID: 22091590 DOI: 10.1586/ern.11.162] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
35
|
Embree LM, Budson AE, Ally BA. Memorial familiarity remains intact for pictures but not for words in patients with amnestic mild cognitive impairment. Neuropsychologia 2012; 50:2333-40. [PMID: 22705441 DOI: 10.1016/j.neuropsychologia.2012.06.001] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2012] [Revised: 06/01/2012] [Accepted: 06/02/2012] [Indexed: 12/01/2022]
Abstract
Understanding how memory breaks down in the earliest stages of Alzheimer's disease (AD) process has significant implications, both clinically and with respect to intervention development. Previous work has highlighted a robust picture superiority effect in patients with amnestic mild cognitive impairment (aMCI). However, it remains unclear as to how pictures improve memory compared to words in this patient population. In the current study, we utilized receiver operating characteristic (ROC) curves to obtain estimates of familiarity and recollection for pictures and words in patients with aMCI and healthy older controls. Analysis of accuracy shows that even when performance is matched between pictures and words in the healthy control group, patients with aMCI continue to show a significant picture superiority effect. The results of the ROC analysis showed that patients demonstrated significantly impaired recollection and familiarity for words compared controls. In contrast, patients with aMCI demonstrated impaired recollection, but intact familiarity for pictures, compared to controls. Based on previous work from our lab, we speculate that patients can utilize the rich conceptual information provided by pictures to enhance familiarity, and perceptual information may allow for post-retrieval monitoring or verification of the enhanced sense of familiarity. Alternatively, the combination of enhanced conceptual and perceptual fluency of the test item might drive a stronger or more robust sense of familiarity that can be accurately attributed to a studied item.
Collapse
|
36
|
In brief. Nat Rev Neurol 2011. [DOI: 10.1038/nrneurol.2011.130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|